Ultralife Corporation Aktie News

Ultralife was removed from the FTSE Russell 3000 Microcap Index due to a share price slump, but fundamentals remain strong, and recovery is underway. Recent earnings show robust revenue and EPS growth, boosted by the Electrochem acquisition and improved productivity, supporting a bullish outlook. The valuation remains attractive, with forecasted EPS growth and a one-year price target of $14.12,...

Ultralife's revenue has been volatile in the past decade or so, but its recent comeback seems to have more legroom to grow. Through a series of recent acquisitions, the company has diversified its revenue dependence on government contracts and obtained access to a more domestic and overseas customer base. Key financial metrics demonstrate strong cash flow and organic integration of its acquisit...

Ultralife Corporation (NASDAQ:ULBI ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Alex Villalta - Investor Relations Mike Manna - President & Chief Executive Officer Phil Fain - Chief Financial Officer Conference Call Participants Josh Sullivan - The Benchmark Company Justin Mechetti - Sidoti & Company Operator Good day and thank you for standing by. Welcome to ...

NEWARK, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights:

Ultralife Corporation (NASDAQ:ULBI ) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Alex Villalta - IR Mike Manna - President and CEO Phil Fain - CFO Conference Call Participants Josh Sullivan - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Ultralife Corporation Fourth Quarter 2024 Results.

Acquisition of Electrochem Completed and Integration Has Commenced                 NEWARK, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:   ULBI) reported operating results for the fourth quarter and full year ended December 31, 2024 as follows: Fourth Quarter: Sales of $43.9 million compared to $44.5 million for the 2023 fourth quarter, including a 11.7% increase in Ba...

NEWARK, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its fourth quarter results for the period ending December 31, 2024 before the market opens on Tuesday, April 1, 2025.

NEWARK, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI), today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.